YWYang Wang

Yang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Wang has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Hua Xu

    Department of Clinical Pharmacy, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College Huazhong University of Science and Technology Wuhan People's Republic of China

    7 shared publications
  • Sichan Li

    Department of Pharmacy, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China

    7 shared publications
  • Jun Wang

    Department of Pharmacy, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

    6 shared publications
  • Chen Chen

    Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Wuhan, China

    5 shared publications
  • Liuliu Gao

    Department of Pharmacy, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

    4 shared publications
  • Sichan Li

    Department of Pharmacy, Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

    4 shared publications

Latest Publications

  • Population pharmacokinetics and dosing regimen optimization of ceftazidime in plasma and cerebrospinal fluid of neonatal sepsis patients

    by Zuo Wang, Yingying Xin, Ying Deng, Ting Xia, Han Ding, Fengliu Chen, Xuwei Tao, Xinyao Jiang, Lingkong Zeng, Yang Wang

  • Open Access

    The efficacy and safety of the ketogenic diet in infantile epileptic spasm syndrome: a meta-analysis

    by CaoXue Zuo, KangJie Xu, Kun Ni, YuXin Xiang, Yang Wang, Zhisheng Liu, Dan Sun


  • Open Access

    Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders

    by Yingying Xin, Liuliu Gao, Sichan Li, Jun Wang, Chen Chen, Yali Tuo, Gang Nie, Ruizhen Li, Dan Sun, Yongli Fu, et al.

    Aripiprazole (ARI) is the first-line treatment for tic disorders (TD). Cytochrome P450(CYP)2D6 (CYP2D6) and ATP-binding cassette, sub-family B, member 1 (ABCB1) transporter are involved in the metabolism of ARI. However, whether CYP2D6 and ABCB1 genetic polymorphisms influence clinical efficacy and pharmacokinetics of ARI remains unclear. CYP2D6 and ABCB1 genotyping were performed. Pharmacokinetic parameters of ARI and its metabolite dehydroaripiprazole (DARI) were derived using a previously established population pharmacokinetic model. Drug response after ARI administration was evaluated based on reduction rate of Yale Global Tic Severity Scale score (YGTSS). Steady-state DARI/ARI metabolic ratios (MRs) of AUC0 − t, Cmin and Cmax were significantly associated with CYP2D6 rs1135840, CYP2D6 rs5030865, CYP2D6 rs1058164, CYP2D6 rs28371702, CYP2D6 rs1065852 and CYP2D6 rs1080989. The clearance (CL) of ARI was influenced by CYP2D6 rs1135840, CYP2D6 rs5030865, and CYP2D6 rs1080989. CYP2D6 rs16947, CYP2D6 rs29001518 and CYP2D6 rs1080985 were correlated with the CL of DARI. The CYP2D6 rs5030865 polymorphism was associated with volume of distribution (V) of DARI. The ABCB1 C3435T (rs1045642) polymorphism influenced the V of ARI. CYP2D6 rs1065852 and CYP2D6 rs1080989 were significantly associated with drug response of ARI. Pharmacokinetic parameters of ARI were correlated with CYP2D6 polymorphisms. CYP2D6 genotyping was recommended in ARI therapy. Further researches are required to elucidate the role of ABCB1 polymorphisms in ARI metabolism.


  • Open Access

    Population Pharmacokinetics and Model-Informed Precision Dosing of Clobazam Based on the Developmental and Genetic Characteristics of Children with Epilepsy

    by Yali Tuo, Xiaolong Yu, Sichan Li, Jun Wang, Maochang Liu, Xinwen Song, Jiehui Ma, Yang Wang, Zhisheng Liu, Dan Sun

    Background/Objectives: This study aimed to characterize the pharmacokinetic profiles of clobazam (CLB) and its active metabolite, N-desmethylclobazam (N-CLB), by establishing a population pharmacokinetic (PPK) model in Chinese children with epilepsy to propose individualized dosing regimens that achieve better clinical outcomes. Methods: This study examined plasma samples collected from 103 pediatric patients with refractory epilepsy undergoing CLB treatment. The plasma concentrations of CLB and its active metabolite N-CLB were measured. The developmental characteristics, CYP2C19 genotype, concomitant medications, and liver and kidney function indicators of the children with epilepsy were considered potential factors affecting the pharmacokinetic characteristics of CLB and N-CLB and analyzed using a PPK modeling approach. Results: A total of 156 samples were attained for PPK model development. The pharmacokinetic profiles of CLB and N-CLB were described using a tandem one-compartment model with first-order elimination. Body weight and CYP2C19 genotype showed statistical significance for CLB and/or N-CLB clearance. The N-CLB/CLB metabolic ratios of AUC24h, Cmin, and Cmax in a steady state were as follows: normal metabolizers (NMs) < intermediated metabolizers (IMs) < poor metabolizers (PMs). The final model achieved good prediction performance and stability. Monte Carlo simulations demonstrated that the trough concentrations of CLB and N-CLB in children with epilepsy could reach satisfactory target values under varying dose regimens in CYP2C19 NMs and IMs, whereas there was a failure to achieve the desired trough concentrations of CLB and N-CLB simultaneously in CYP2C19 PMs due to the accumulation of N-CLB. Conclusions: Body weight and CYP2C19 genotype had an impact on CLB and/or N-CLB clearance in children with epilepsy. To ensure safe treatment, it is recommended to use the concentration of N-CLB as the target indicator for therapeutic drug monitoring and dose adjustments in CYP2C19 PMs. These results provide evidence for guiding the precise use of CLB.


  • Open Access

    Population pharmacokinetics and dose optimization of ceftazidime in critically ill children

    by Mengting Li, Liuliu Gao, Zuo Wang, Lingkong Zeng, Chen Chen, Jun Wang, Sichan Li, Maochang Liu, Yang Wang

    Objective: The aim of this study was to develop a population pharmacokinetic model for ceftazidime in critically ill children in the pediatric intensive care unit (PICU) and optimize an appropriate dosing regimen for this population.Methods: We performed a prospective pharmacokinetic study on critically ill children aged 0.03–15 years. A population pharmacokinetic model was developed using the NLME program. Statistical and graphical methods were used to assess the stability and predictive performance of the model. Monte Carlo simulations were conducted to determine the optimal ceftazidime dosing regimen to achieve 70% fT > minimum inhibitory concentration (MIC).Results: This study included 88 critically ill children and 100 ceftazidime serum concentrations. The pharmacokinetic characteristics of ceftazidime were best described by a one-compartment linear elimination model. The weight and estimated glomerular filtration rate (eGFR) were determinant covariates for the clearance (CL) of ceftazidime. The recommended ceftazidime dosage regimens achieved a probability of target attainment (PTA) >90% for critically ill children at MIC values of 2, 4, and 8 mg/L. For bacterial infection at an MIC of 16 mg/L, it is difficult to achieve effective pharmacodynamic (PD) targets in vivo with the commonly used dose of ceftazidime.Conclusion: The population pharmacokinetic model of ceftazidime was established in critically ill children. Based on this model, we recommend evidence-based, individualized dosing regimens for subgroups with different weights and renal functions. The current daily dosage for children adequately meets the treatment requirements for MICs of 2, 4, and 8 mg/L, while for bacterial infection at an MIC of 16 mg/L, an elevated dosage regimen may be required.Clinical Trial Registration: https://www.medicalresearch.org.cn/login, Identifier MR-42-22-000220.


  • How to handle a missed or delayed dose of lacosamide in pediatric patients with epilepsy? a mode-informed individual dosing

    by Jun Wang, Yan Mei, Song Liang, Si-Chan Li, Chen Chen, Gang Nie, Ya-Li Tuo, Dan Sun, Yang Wang


  • Open Access

    Ornidazole Transfer into Colostrum and Assessment of Exposure Risk for Breastfeeding Infant: A Population Pharmacokinetic Analysis

    by Sichan Li, Ming Cao, Yan Zhou, Chang Shu, Yang Wang

    Ornidazole is frequently used for the prevention and treatment of anaerobic infections after caesarean section. There is still a lack of data on the excretion of ornidazole in breast milk. Therefore, the aim of this study was to investigate the transfer of ornidazole into colostrum and to assess the risk of infant exposure to the drug via breast milk. Population pharmacokinetic analysis was conducted using datasets of plasma and milk concentrations obtained from 77 breastfeeding women to examine the excretion kinetics of ornidazole. Various factors that may affect the excretion of ornidazole were investigated. The final model was then used to simulate ornidazole concentration–time profiles in both plasma and milk. The drug exposure in body fluids and the potential risk for breastfeeding were assessed based on the safety threshold. Plasma ornidazole concentration data could be described well by a one-compartment model, and concentrations in breast milk were linked to this model using an estimated milk-to-plasma concentration ratio (MPRcon). Significant variables that influenced drug exposure and MPRcon were identified as total bilirubin levels (TBIL) and postnatal sampling time, respectively. Simulations showed that women with abnormal liver function (TBIL > 17 μmol/L) had higher ornidazole levels in plasma and milk than those with normal liver function (TBIL < 17 μmol/L), but the exposures through colostrum of lactating women from both groups were below the safety threshold. This work provides a simple and feasible strategy for the prediction of drug exposure in breast milk and the assessment of breastfeeding safety.


  • Open Access

    Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes

    by Yingying Xin, Liuliu Gao, Yali Tuo, Gang Nie, Yan Mei, Chen Chen, Jun Wang, Sichan Li, Dan Sun, Qiaoqiao Qian, et al.

    Objective: This study aims to develop a combined population pharmacokinetic (PPK) model for aripiprazole (ARI) and its main active metabolite dehydroaripiprazole (DARI) in pediatric patients with tic disorders (TD), to investigate the inter-individual variability caused by physiological and genetic factors in pharmacokinetics of ARI and optimize the dosing regimens for pediatric patients.Methods: A prospective PPK research was performed in Chinese children with TD. Totally 84 patients aged 4.83–17.33 years were obtained for the pharmacokinetic analysis. 27 CYP2D6 and ABCB1 gene alleles were detected. Moreover, the clinical efficacy was evaluated according to reduction rate of Yale Global Tic Severity Scale (YGTSS) score at the 12th week comparing with the baseline. Monte Carlo simulations were used to evaluate and optimize dosing regimens.Results: The PPK model was established to predict the concentrations of ARI and DARI. Body weight and CYP2D6 genotype were the significant covariates affecting the clearance of ARI. The DARI/ARI metabolic ratios (MRs) of AUC24h, Cmin and Cmax at the steady state of results were ultra-rapid metabolizers (UMs) > normal metabolizers (NMs) > intermediated metabolizers (IMs). MRs could be used to distinguish UMs or IMs from other patients. The best predictor of clinical efficacy for TD was the trough concentration of ARI and the cut-off point was 101.636 ng/ml.Conclusion: The pharmacokinetics of ARI and DARI in pediatric TD were significantly influenced by body weight and CYP2D6 genotype. Individualized dosing regimens were recommended for pediatric patients with TD to ensure clinical efficacy.


  • Open Access

    Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients

    by Peng Cao, Wei Guo, Jun Wang, Sanlan Wu, Yifei Huang, Yang Wang, Yani Liu, Yu Zhang

    The purposes of this study were to identify physiological and genetic factors that contributed to variability of pemetrexed (PEM) exposure and to optimize the dosing regimens for Chinese non-small cell lung carcinoma patients. A prospective population pharmacokinetics (PPK) research was performed in this population. The PEM concentrations of 192 plasma samples from 116 in-hospital patients were detected. All patients were genotyped for polymorphisms. The PPK model of PEM was developed. The pharmacokinetic behavior of PEM was described by a two-compartment model with first-order elimination. The population typical values were as follows: clearance (CL) 8.29 L/h, intercompartmental clearance (Q) 0.10 L/h, central volume of distribution (V1) 18.94 L and peripheral volume of distribution (V2) 5.12 L. Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. By using empirical body surface area (BSA)-based dosing strategy, PEM exposure decreased with the elevation of CrCl. Contrarily, CrCl-based dosing strategy exhibited a satisfactory efficacy of achieving the target PEM exposure. BSA-based dosing regimen in current clinic practice is not suitable to achieve the target exposure in PEM chemotherapy of Chinese NSCLC patients. Alternatively, renal function-based dosing strategy is suggested.